Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Upside (ABEO)

This article was written by Follow We target small and microcap biopharmaceuticals companies where our advantage…

Sable Offshore Has One Last Regulatory Hurdle Before Operating (Rating Upgrade) (NYSE:SOC)

This article was written by Follow Michael Del Monte is a buy-side equity analyst with over…